Uncovering Key Drug Opportunities to Combat Aging and Neurodegenerative Diseases

The complex process of aging is a major risk factor for numerous chronic conditions, including debilitating neurodegenerative diseases like Alzheimer's disease and Parkinson's disease. Despite significant research, effective therapeutic strategies to slow or reverse age-related decline and treat these conditions remain limited. This review article from 2000 aimed to identify promising molecular targets and emerging drug classes that could offer novel interventions for aging and age-related pathologies.

The review identified several critical areas for drug development. It highlighted growth hormone secretagogue receptor agonists as potential rejuvenating agents, suggesting their role in combating aspects of aging. For Alzheimer's disease, the authors noted the identification of two critical enzymes involved in the formation of beta-amyloid plaques, which are hallmarks of the disease, as promising drug targets. Furthermore, estrogen receptor beta was recognized as an emerging therapeutic target, potentially offering benefits beyond traditional hormonal roles. In the context of Parkinson's disease, the orphan nuclear receptor Nurr1 (Nuclear Receptor Subfamily 4, Group A, Member 2) was pinpointed as a significant target, with propargylamines emerging as inhibitors of oxidative damage in neurons. The review's most significant finding was the identification of multiple distinct molecular pathways and targets, offering a diverse array of potential pharmacological interventions to address the multifaceted challenges of aging and neurodegeneration.